Cargando…

P564: HOMOHARRINGTONINE AND CYTARABINE COMBINED WITH VENETOCLAX (HAV) FOR ADULT PATIENTS WITH DE NOVO AML

Detalles Bibliográficos
Autores principales:	Luo, Xiao-Hua, Liu, Lin, Yang, LI, Zhu, Yan, Xiao, Qing, Wang, LI, Wang, Xin, Chen, Jian-Bin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10429144/ http://dx.doi.org/10.1097/01.HS9.0000969160.99814.64

Ejemplares similares

P507: SALVAGE THERAPY WITH VENETOCLAX IN COMBINATION WITH AZACITIDINE, HOMOHARRINGTONINE AND CYTARABINE IN PATIENTS WITH RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA
por: Yuan, Linyu, et al.
Publicado: (2023)

Venetoclax Combined with Azacitidine and Homoharringtonine in Relapsed/Refractory AML: A Multicenter, Phase 2 Trial
por: Jin, Hua, et al.
Publicado: (2023)

Outcomes of venetoclax combined with homoharringtonine and cytarabine in fit adults patients with de novo adverse‐risk acute myeloid leukaemia: A single‐centre retrospective analysis
por: Song, Bao‐Quan, et al.
Publicado: (2023)

Treatment of STAT5b-RARA positive acute promyelocytic leukemia by Venetoclax combining with homoharringtonine, cytarabine: A case report and literature review
por: Zhang, Guangji, et al.
Publicado: (2022)

High efficacy of azacitidine combined with homoharringtonine, idarubicin, and cytarabine in newly diagnosed patients with AML: A single arm, phase 2 trial
por: Li, Jun, et al.
Publicado: (2022)

The Metabolic Signature of AML Cells Treated With Homoharringtonine
por: Zhang, Yulong, et al.
Publicado: (2022)

Homoharringtonine combined with aclarubicin and cytarabine synergistically induces apoptosis in t(8;21) leukemia cells and triggers caspase‐3‐mediated cleavage of the AML1‐ETO oncoprotein
por: Cao, Jiang, et al.
Publicado: (2016)

P553: PRELIMINARY RESULTS OF MRD ANALYSIS OF AML1718, A PHASE 2 OPEN-LABEL STUDY OF VENETOCLAX, FLUDARABINE, IDARUBICIN AND CYTARABINE (V-FLAI) IN THE INDUCTION THERAPY OF NON LOW-RISK AML
por: Minetto, Paola, et al.
Publicado: (2023)

Synergistic efficacy of homoharringtonine and venetoclax on acute myeloid leukemia cells and the underlying mechanisms
por: Yuan, Fangfang, et al.
Publicado: (2022)

P578: EFFECTIVENESS OF REINDUCTION CHEMOTHERAPY USING BORTEZOMIB WITH HOMOHARRINGTONINE AND CYTARABINE IN REFRACTORY OR RELAPSED ACUTE MYELOID LEUKEMIA: A PHASE II, MULTICENTER, PROSPECTIVE CLINICAL TRIAL
por: Zhang, Chengtao, et al.
Publicado: (2023)

P584: VENETOCLAX PLUS HOMOHARRINGTONINE-BASED CHEMOTHERAPY AS FIRST-LINE TREATMENT FOR ADULTS WITH ACUTE MYELOID LEUKAEMIA: A MULTICENTRE, SINGLE-ARM, PHASE 2 TRIAL
por: Wang, Huafeng, et al.
Publicado: (2023)

Efficacy and safety of decitabine combined with HAAG (homoharringtonine, aclarubicin, low-dose cytarabine and G-CSF) for newly diagnosed acute myeloid leukemia
por: Zhu, Jun-Feng, et al.
Publicado: (2022)

EIF4A inhibition targets bioenergetic homeostasis in AML MOLM-14 cells in vitro and in vivo and synergizes with cytarabine and venetoclax
por: Fooks, Katie, et al.
Publicado: (2022)

P555: OLUTASIDENIB IN POST-VENETOCLAX PATIENTS WITH MUTANT IDH1 AML
por: Cortes, Jorge, et al.
Publicado: (2023)

PB1925: VENETOCLAX IN COMBINATION WITH AZACITIDINE OR LOW-DOSE CYTARABINE IN PATIENTS WITH HIGH-RISK MDS AND AML - EXPERIENCE OF A CZECH HAEMATOLOGY CENTRE.
por: Minarik, L., et al.
Publicado: (2022)

Artesunate improves venetoclax plus cytarabine AML cell targeting by regulating the Noxa/Bim/Mcl-1/p-Chk1 axis
por: Zhang, Jingyi, et al.
Publicado: (2022)

Cytarabine/venetoclax: Recurrent Corynebacterium bacteraemia: case report
Publicado: (2022)

P488: SAFETY AND EFFICACY OF VENETOCLAX PLUS “7 + 3” CHEMOTHERAPY IN NEWLY DIAGNOSED AML
por: Mantzaris, Ioannis, et al.
Publicado: (2023)

Venetoclax plus cyclophosphamide and cytarabine as induction regimen for adult acute myeloid leukemia
por: Zhang, Baohang, et al.
Publicado: (2023)

Enhanced sensitivity to glucocorticoids in cytarabine-resistant AML
por: Malani, D, et al.
Publicado: (2017)

Effectiveness of chemotherapy using bortezomib combined with homoharringtonine and cytarabine in refractory or relapsed acute myeloid leukemia: a phase II, multicenter, prospective clinical trial
por: Zhang, Chengtao, et al.
Publicado: (2023)

921. Acute HAV Infection in an Inpatient Psychiatry Unit
por: Weston, Gregory, et al.
Publicado: (2021)

P426: HDAC INHIBITORS RESTORE SENSITIVITY TO VENETOCLAX AND NAVITOCLAX IN AML CELLS RESULTING IN THE IRREVERSIBLE DNA DAMAGE
por: Khabusheva, Elmira, et al.
Publicado: (2023)

P521: FINDINGS FROM AN ANALYSIS OF PATIENTS WITH MONOCYTIC AND MONOCYTIC-LIKE ACUTE MYELOID LEUKEMIA (AML), INCLUDING AML-M4 AND AML-M5, TREATED WITH VENETOCLAX (VEN) PLUS AZACITIDINE (AZA)
por: Konopleva, Marina, et al.
Publicado: (2023)

P532: KINETICS AND PROGNOSTIC VALUE OF MEASURABLE RESIDUAL DISEASE (MRD) IN PATIENTS DIAGNOSED WITH ACUTE MYELOID LEUKEMIA (AML) TREATED WITH VENETOCLAX IN COMBINATION WITH HYPOMETHYLATING AGENTS.
por: Jimenez-Vicente, Carlos, et al.
Publicado: (2023)

P572: REAL-WORLD MANAGEMENT AND OUTCOMES FOR NEWLY DIAGNOSED AML PATIENTS INITIATING VENETOCLAX AND HYPOMETHYLATING AGENTS IN US COMMUNITY PRACTICE
por: Wang, Yuexi, et al.
Publicado: (2023)

Prevalence of HAV and HEV in the patients presenting with acute viral hepatitis
por: Rao, Pooja, et al.
Publicado: (2012)

Case report of combination therapy with Azacytidine, Enasidenib and Venetoclax in primary refractory AML
por: Jasra, Sakshi, et al.
Publicado: (2021)

Three kinds of treatment with Homoharringtonine, Hydroxychloroquine or shRNA and their combination against coronavirus PEDV in vitro
por: Li, Cui-Cui, et al.
Publicado: (2020)

Review of Venetoclax in CLL, AML and Multiple Myeloma
por: Lasica, Masa, et al.
Publicado: (2021)

PB1857: VENETOCLAX, AZACITIDINE, COMBINED WITH LOW-DOSE CYTARABINE IN OLDERLY OR UNFIT PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA
por: Han, Xiao, et al.
Publicado: (2023)

Homoharringtonine-Based Induction Regimen Improved the Remission Rate and Survival Rate in Chinese Childhood AML: A Report From the CCLG-AML 2015 Protocol Study
por: Li, Jing, et al.
Publicado: (2023)

HAG (Homoharringtonine, Cytarabine, G-CSF) Regimen for the Treatment of Acute Myeloid Leukemia and Myelodysplastic Syndrome: A Meta-Analysis with 2,314 Participants
por: Xie, Mixue, et al.
Publicado: (2016)

Ceramide nanoliposomes augment the efficacy of venetoclax and cytarabine in models of acute myeloid leukemia
por: Khokhlatchev, Andrei V., et al.
Publicado: (2022)

Acute myeloid leukemia in an 86-year-old man with AML1/ETO treated with Homoharringtonine and Arsenic Trioxide: A case report
por: He, Zhipeng, et al.
Publicado: (2019)

P545: VENETOCLAX (VEN) COMBINED WITH FLAG-IDA IS AN EFFECTIVE REGIMEN FOR PATIENTS (PTS) WITH NEWLY DIAGNOSED (ND) AND RELAPSED/REFRACTORY (R/R) ACUTE MYELOID LEUKEMIA (AML)
por: Burkart, Madelyn, et al.
Publicado: (2023)

The combination effect of homoharringtonine and ibrutinib on FLT3-ITD mutant acute myeloid leukemia
por: Li, Xia, et al.
Publicado: (2017)

The Natural Compound Homoharringtonine Presents Broad Antiviral Activity In Vitro and In Vivo
por: Dong, Hui-Jun, et al.
Publicado: (2018)

Augmenting Venetoclax Activity Through Signal Transduction in AML
por: Bouligny, Ian Michael, et al.
Publicado: (2023)

P418: DELE1 LOSS AND DYSFUNCTIONAL INTEGRATED STRESS SIGNALING IN TP53 MUTATED AML IS A NOVEL PATHWAY FOR VENETOCLAX RESISTANCE
por: Sharon, David, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_a97ft95bslmthg5o3p3vat7n4l